At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. By safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today.
Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early.
By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.
Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early.
By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $183M
Founded date: 2009
Investors 9
Funding Rounds 6
| Date | Series | Amount | Investors |
| 23.03.2021 | - | $80M | - |
| 02.04.2019 | Series D | $40M | - |
| 21.12.2017 | Series C | $30M | Arix Biosc... |
| 29.09.2016 | - | $8M | - |
| 05.03.2015 | Series B | $21M | - |
| 15.08.2014 | - | $4M | - |
Mentions in press and media 35
| Date | Title | Description |
| 01.05.2026 | Jason Chambers Teams Up with the Melanoma Research Foundation to #GetNaked for Melanoma Awareness Month | The Melanoma Research Foundation (MRF) is pleased to announce the launch of its annual award-winning #GetNaked campaign recognizing the melanoma patient community during Melanoma Awareness Month. In 2026, the MRF is joined by Superyacht Cap... |
| 12.03.2024 | Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened Capital Position from Registered Direct Equ... |
| 03.05.2023 | WCVB Channel 5 Chronicle Reporter and Producer Nicole Estaphan to Emcee Melanoma Research Foundation’s Miles for Melanoma 5K | BOSTON (PRWEB) May 03, 2023 The Melanoma Research Foundation (MRF) is thrilled to announce that WCVB Channel 5 Chronicle Reporter and Producer Nicole Estaphan will be returning as the event emcee for the annual Miles for Melanoma New Englan... |
| 22.11.2022 | Aura, the frame and photo startup, raises $26M as it nears 3M app users with 1M frames sold | Aura, a startup founded by early Twitter employees that makes digital frames and photo sharing apps that can also be used to update those frames, has pulled in some funding to expand its business as it closes in on three million users of it... |
| 07.11.2022 | Prevent Blindness Names Jim McGrann Chair of its Board of Directors, Adds Dr. Susan A. Primo, MPH, FAAO, and Susan L. Stone, MBA, as New Members | Jim McGrann, CEO of Professional Eyecare Associates of America (PECAA), named Chair of the Prevent Blindness Board of Directors. “I’m looking forward to working closely with Jim McGrann in his new leadership role at Prevent Blindness,” said... |
| 03.11.2021 | Ysios Capital anuncia la salida a bolsa en el NASDAQ de su compañía participada Aura Biosciences | 03/11/2021 Nota de prensa YSIOS CAPITAL ANUNCIA LA SALIDA A BOLSA EN EL NASDAQ DE SU COMPAÑÍA PARTICIPADA AURA BIOSCIENCES. − Aura Biosciences (Cambridge, Estados Unidos), fundada por la española Elisabet de los Pinos, está desarrollando... |
| 03.11.2021 | Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ | 03/11/2021 Press release YSIOS CAPITAL’S PORTFOLIO COMPANY AURA BIOSCIENCES PRICES IPO ON NASDAQ. − Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (V... |
| 23.03.2021 | Aura Biosciences picks up $80M | Aura Biosciences has raised $80 million in a round co-led by Matrix Capital Management and Surveyor Capital. The Boston-area company is developing ocular cancer treatments and plans to use the funding in part to accelerate clinical developm... |
| 22.03.2021 | Aura Biosciences Announces Oversubscribed $80 Million Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2021-- Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an... |
| 22.03.2021 | Aura Biosciences cierra una ronda de $80M liderada por Matrix Capital y Surveyor. Acuden también Ysios, Adage Capital, Rock Springs, Velosity Capital e inversores actuales | 22/03/2021 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE FINANCIACIÓN DE $80 MILLONES DE SU PARTICIPADA AURA BIOSCIENCES. − Aura Biosciences (Estados unidos), fundada por la española Elisabet de los Pinos, está desarrollando una ... |
Show more